Genome-Wide Methylation Analyses in Glioblastoma Multiforme
Open accessThe DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Abstract
Few studies had investigated genome-wide methylation in glioblastoma multiforme (GBM). Our goals were to study differential methylation across the genome in gene promoters using an array-based method, as well as repetitive elements using surrogate global methylation markers. The discovery sample set for this study consisted of 54 GBM from Columbia University and Case Western Reserve University, and 24 brain controls from the New York Brain Bank. We assembled a validation dataset using methylation data of 162 TCGA GBM and 140 brain controls from dbGAP. HumanMethylation27 Analysis Bead-Chips (Illumina) were used to interrogate 26,486 informative CpG sites in both the discovery and validation datasets. Global methylation levels were assessed by analysis of L1 retrotransposon (LINE1), 5 methyl-deoxycytidine (5m-dC) and 5 hydroxylmethyl-deoxycytidine (5hm-dC) in the discovery dataset. We validated a total of 1548 CpG sites (1307 genes) that were differentially methylated in GBM compared to controls. There were more than twice as many hypomethylated genes as hypermethylated ones. Both the discovery and validation datasets found 5 tumor methylation classes. Pathway analyses showed that the top ten pathways in hypomethylated genes were all related to functions of innate and acquired immunities. Among hypermethylated pathways, transcriptional regulatory network in embryonic stem cells was the most significant. In the study of global methylation markers, 5m-dC level was the best discriminant among methylation classes, whereas in survival analyses, high level of LINE1 methylation was an independent, favorable prognostic factor in the discovery dataset. Based on a pathway approach, hypermethylation in genes that control stem cell differentiation were significant, poor prognostic factors of overall survival in both the discovery and validation datasets. Approaches that targeted these methylated genes may be a future therapeutic goal.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures








Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“BT142 G-CIMP status was confirmed by evaluating LINE methylation with the “Global DNA Methylation Assay – LINE-1″ kit (Active Motif), as described36, and by methylation-sensitive restriction digests.”
From Insulator dysfunction and oncogene activation in IDH mutant gliomas (2016) · cites this paper as [36]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A decade of exploring the cancer epigenome—biological and translational implications
Baylin, S. B., & Jones, P. A. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3130 · Cited by 2,871 · cited 2×
“Moreover, it appeared that the DNA demethylating agent, 5-deoxy-azacytidine (DAC) was able to reverse methylation and induce gene expression in cancer cells that were marked by both repressive chromatin marks (positive for H3K27me(3)) and methylation, but histone deacetylase inhibitor (HDACi) was not able to re-activa…”
BackgroundIdentification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of Glioma
Noushmehr, H., Weisenberger, D. J., Diefes, K., Phillips, H. S., Pujara, K., Berman, B. P., Pan, F., Pelloski, C. E., Sulman, E. P., Bhat, K. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.03.017 · Cited by 2,337 · cited 5×
“Determination of Glioma CpG Island Methylator Phenotype (GCIMP) Status In both the discovery and validation datasets, we found those probes in the Illumina 27 K array that corresponded to the validated GCIMP markers as documented by Noushmehr et al [6].”
BackgroundMethodResultInfluentialControl of Developmental Regulators by Polycomb in Human Embryonic Stem Cells
Lee, T. I., Jenner, R. G., Boyer, L. A., Guenther, M. G., Levine, S. S., Kumar, R. M., Chevalier, B., Johnstone, S. E., Cole, M. F., Isono, K.-I., et al. (2006) · Cell · doi:10.1016/j.cell.2006.02.043 · Cited by 2,268 · cited 1×
“To quantify the degree of enrichment in our validated genes, we queried CHIP-seq datasets of H1-hESC (Tier 1) in ENCODE and from published papers [35,36].”
MethodRepetitive DNA and next-generation sequencing: computational challenges and solutions
Treangen, T. J., & Salzberg, S. L. (2012) · Nature Reviews Genetics · doi:10.1038/nrg3117 · Cited by 1,597 · cited 1×
“Despite their abundance and importance in tumorigenesis, the sequences and maps of repetitive elements in the genome have been difficult to ascertain, because repeats created ambiguities in alignment and in genome assembly [13].”
BackgroundRepetitive Elements May Comprise Over Two-Thirds of the Human Genome
de Koning, A. P. J., Gu, W., Castoe, T. A., Batzer, M. A., & Pollock, D. D. (2011) · PLoS Genetics · doi:10.1371/journal.pgen.1002384 · Cited by 1,112 · cited 2×
“Repetitive elements may comprise over two-thirds of the human genome, and a high proportion of them are retrotransposons, whose expression is normally suppressed by methylation of cytosine [10].”
BackgroundIncreased methylation variation in epigenetic domains across cancer types
Hansen, K. D., Timp, W., Bravo, H. C., Sabunciyan, S., Langmead, B., McDonald, O. G., Wen, B., Wu, H., Liu, Y., Diep, D., et al. (2011) · Nature Genetics · doi:10.1038/ng.865 · Cited by 1,045
Hegi, M. E., Liu, L., Herman, J. G., Stupp, R., Wick, W., Weller, M., Mehta, M. P., & Gilbert, M. R. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.5964 · Cited by 812 · cited 1×
“Nevertheless, in GBM, demethylating agents have not been considered in clinical trials because promoter MGMT methylation is related to temozolomide (TMZ) response [41].”
BackgroundAbundant quantitative trait loci exist for DNA methylation and gene expression in human brain
Gibbs, J. R., van der Brug, M. P., Hernandez, D. G., Traynor, B. J., Nalls, M. A., Lai, S.-L., Arepalli, S., Dillman, A., Rafferty, I. P., Troncoso, J., et al. (2010) · PLoS Genetics · doi:10.1371/journal.pgen.1000952 · Cited by 769 · cited 1×
“The methylation results using Illumina Methylation 27 K platform were published previously [22].”
MethodUncovering the role of 5-hydroxymethylcytosine in the epigenome
Branco, M. R., Ficz, G., & Reik, W. (2012) · Nature Reviews Genetics · doi:10.1038/nrg3080 · Cited by 766 · cited 1×
“Although it is also a global methylation marker and is closely related to 5m-dC, 5hm-dC is enriched within the gene body, promoters and transcription start site, whereas 5m-dC and LINE1 were primarily located in heterochromatin and repetitive elements [43].”
BackgroundLandscape of Somatic Retrotransposition in Human Cancers
Lee, E., Iskow, R., Yang, L., Gokcumen, O., Haseley, P., Luquette, L. J., Lohr, J. G., Harris, C. C., Ding, L., Wilson, R. K., et al. (2012) · Science · doi:10.1126/science.1222077 · Cited by 762 · cited 1×
“This can lead to transposable elements insertion, and some of them, such as L1, can express their RNAs, which then promote DNA damage, spreading of methylation to promoters and genomic deletions [11,12].”
Background
Cited by
Insulator dysfunction and oncogene activation in IDH mutant gliomas
Flavahan, W. A., Drier, Y., Liau, B. B., Gillespie, S. M., Venteicher, A. S., Stemmer-Rachamimov, A. O., Suvà, M. L., & Bernstein, B. E. (2016) · Nature · doi:10.1038/nature16490 · Cited by 1,288
Circulating biomarkers for gliomas
Westphal, M., & Lamszus, K. (2015) · Nature Reviews Neurology · doi:10.1038/nrneurol.2015.171 · Cited by 181
Lee, W., Johnson, J., Gough, D. J., Donoghue, J., Cagnone, G. L. M., Vaghjiani, V, Brown, K. A., Johns, T. G., & St. John, J. C. (2015) · Cell Death & Disease · doi:10.1038/cddis.2015.34 · Cited by 129
“However, cancer cells, such as those giving rise to Glioblastoma multiforme, the most aggressive malignant primary brain tumour,(18,19) are extensively DNA methylated.(20) When induced to differentiate, they fail to increase mtDNA copy number and continue to express NESTIN, MUSASHI1 and CD133.”
BackgroundPark, A. K., Kim, P., Ballester, L. Y., Esquenazi, Y., & Zhao, Z. (2018) · Neuro-Oncology · doi:10.1093/neuonc/noy120 · Cited by 112
Brigliadori, G., Foca, F., Dall’Agata, M., Rengucci, C., Melegari, E., Cerasoli, S., Amadori, D., Calistri, D., & Faedi, M. (2016) · Journal of Neuro-Oncology · doi:10.1007/s11060-016-2116-y · Cited by 70
“Methylation status of each CpG island in the promoter region of many genes like MGMT have already been investigated [24] to evaluate their role in gene silencing.”
BackgroundPapillary Tumor of the Pineal Region: A Distinct Molecular Entity
Heim, S., Sill, M., Jones, D., Vasiljevic, A., Jouvet, A., Fèvre‐Montange, M., Wesseling, P., Beschorner, R., Mittelbronn, M. G. A., Kohlhof, P., et al. (2015) · Brain Pathology · doi:10.1111/bpa.12282 · Cited by 63
“DNA methylation profiling has been successfully applied to FFPE tissue samples to delineate different tumor entities (8) and subgroups (8, 13).”
The onco-immunological implications of Fusobacterium nucleatum in breast cancer
van der Merwe, M., van Niekerk, G., Botha, A., & Engelbrecht, A. (2021) · Immunology Letters · doi:10.1016/j.imlet.2021.02.007 · Cited by 56
Molecular Predictors of Long-Term Survival in Glioblastoma Multiforme Patients
Lu, J., Cowperthwaite, M. C., Burnett, M. G., & Shpak, M. (2016) · PLoS ONE · doi:10.1371/journal.pone.0154313 · Cited by 54
Global hypomethylation is an independent prognostic factor in diffuse large B cell lymphoma
Wedge, E., Hansen, J. W., Garde, C., Asmar, F., Tholstrup, D., Kristensen, S. S., Munch-Petersen, H. R., Ralfkiaer, E. M., Brown, P. D. N., Grønbæk, K., et al. (2017) · American Journal of Hematology · doi:10.1002/ajh.24751 · Cited by 53
“Also, supporting this evidence, LINE1 hypermethylation is described as a positive prognostic factor in glioblastoma multiforme.(10) Circulating cell-free DNA (cfDNA) offers the possibility for molecular diagnostics in cancer using peripheral blood samples, termed a liquid biopsy.”
BackgroundDistinguishing Glioblastoma Subtypes by Methylation Signatures
Zhang, Y., Li, Z., Zeng, T., Pan, X., Chen, L., Liu, D., Li, H., Huang, T., & Cai, Y. (2020) · Frontiers in Genetics · doi:10.3389/fgene.2020.604336 · Cited by 42
Liu, L., Wang, G., Wang, L., Yu, C., Li, M., Song, S., Hao, L., Ma, L., & Zhang, Z. (2020) · Biology Direct · doi:10.1186/s13062-020-00264-5 · Cited by 36
Majchrzak‐Celińska, A., Dybska, E., & Barciszewska, A. (2020) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.13443 · Cited by 31
Cai, J., Zeng, C., Hua, W., Qi, Z., Song, Y., Lu, X., Li, D., Zhang, Z., Cui, X., Zhang, X., et al. (2021) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdab049 · Cited by 31
Xin, X., He, J., & Qiu, W. (2017) · Environmental Science and Pollution Research · doi:10.1007/s11356-017-0834-0 · Cited by 33
Hopp, L., Loeffler‐Wirth, H., Galle, J., & Binder, H. (2018) · Epigenomics · doi:10.2217/epi-2017-0140 · Cited by 30
An Update on the Epigenetics of Glioblastomas
Ferreira, W. A. S., Pinheiro, D. D. R., da Costa, C. A., Rodrigues-Antunes, S., Araújo, M. D., Barros, M. B. L., Teixeira, A. C. D. S., Faro, T. A. S., Burbano, R. M. R., de Oliveira, E. H. C., et al. (2016) · Epigenomics · doi:10.2217/epi-2016-0040 · Cited by 30
A novel prognostic six‐CpG signature in glioblastomas
Yin, A., Lu, N., Etcheverry, A., Aubry, M., Barnholtz‐Sloan, J. S., Zhang, L., Mosser, J., Zhang, W., Zhang, X., Liu, Y., et al. (2018) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12786 · Cited by 30
“repository including GSE50923_27k (GBMs, n=54; NBs, n=24) [15], GSE60274_450k (GBMs, n=64; NBs, n=5) [16] and GSE36278_450k (GBMs, n=57; tumors harboring mutations in H3F3A and those from TCGA were excluded) [17].”
BackgroundSelf-citationGenome-wide methylation profiling reveals new biomarkers for prognosis prediction of glioblastoma
He, C., Ma, J., Hou, X., Li, M., Ren, H., Fang, S., & Wang, X. (2015) · Journal of Cancer Research and Therapeutics · doi:10.4103/0973-1482.168188 · Cited by 27
Loss of type I IFN responsiveness impairs natural killer cell antitumor activity in breast cancer
Zanker, D. J., Owen, K. L., Baschuk, N., Spurling, A., & Parker, B. S. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-021-02857-z · Cited by 29
Phage Interactions with the Nervous System in Health and Disease
Jędrusiak, A., Fortuna, W., Majewska, J., Górski, A., & Jończyk‐Matysiak, E. (2023) · Cells · doi:10.3390/cells12131720 · Cited by 27
“59 to 5 per 100,000 persons internationally [187], with a median life expectancy of approximately 14–16 months [188], and only 5% of all patients surviving to 5 years post diagnosis [189].”
BackgroundAcute exposure to methamphetamine alters TLR9-mediated cytokine expression in human macrophage
Burns, A. M., & Ciborowski, P. S. (2015) · Immunobiology · doi:10.1016/j.imbio.2015.09.006 · Cited by 25
Iwadate, Y., Suganami, A., Tamura, Y., Matsutani, T., Hirono, S., Shinozaki, N., Hiwasa, T., Takiguchi, M., & Saeki, N. (2017) · Neurosurgery · doi:10.1093/neuros/nyw026 · Cited by 19
Yin, A., Shang, Z., Etcheverry, A., He, Y., Aubry, M., Lü, N., Liu, Y., Mosser, J., Lin, W. J., Zhang, X., et al. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1902071 · Cited by 20
Evelönn, E. A., Degerman, S., Köhn, L., Landfors, M., Ljungberg, B., & Roos, G. (2016) · Tumor Biology · doi:10.1007/s13277-016-4893-5 · Cited by 18
Assessment of Changes in Global DNA Methylation Levels by Pyrosequencing® of Repetitive Elements
Tabish, A. M., Baccarelli, A., Godderis, L., Barrow, T. M., Hoet, P., & Byun, H. (2015) · Methods in molecular biology · doi:10.1007/978-1-4939-2715-9_15 · Cited by 20
Novel predictive epigenetic signature for temozolomide in non-G-CIMP glioblastomas
Yin, A., He, Y., Etcheverry, A., Liu, Y., Aubry, M., Barnholtz‐Sloan, J. S., Liu, B.-L., Mosser, J., Lu, Z.-F., & Zhang, X. (2019) · Clinical Epigenetics · doi:10.1186/s13148-019-0670-9 · Cited by 18
Self-citationZhang, M., Lv, X., Jiang, Y., Li, G., & Qiao, Q. (2019) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2019.7807 · Cited by 19
“The median methylation level (β‐values) of specific CpG sites in normal brain tissue and tumour tissue, median β differences between normal tissue and tumour tissue, and P-values (computed by a non-parametric Wilcoxon Rank-Sum test) were available from the supplementary materials of the published study (19).”
MethodInfluentialIntegrative analysis of novel hypomethylation and gene expression signatures in glioblastomas
Yin, A., Etcheverry, A., He, Y., Aubry, M., Barnholtz‐Sloan, J. S., Zhang, L., Mao, X., Chen, W., Liu, B., Zhang, W., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.19171 · Cited by 19
“[16]) and a European cohort (n = 144) with only gene expression data (GSE16011; ref.”
BackgroundMethodInfluentialSelf-citationSalazar, F. E., Pérez, R. M., Cano-Herrera, G., Bautista-Gonzalez, M. F., Loza-López, E. C., Vionet, A. M., van Tienhoven, X. A., Chumaceiro-Natera, A., Aldaba, E. S., & Ibarra, A. (2025) · Biomedicines · doi:10.3390/biomedicines13081882 · Cited by 20
“Even when partially disrupted within the tumor core, an intact BBB in infiltrative margins continues to limit treatment efficacy [6].”
Genome‑wide DNA methylation regulation analysis of long non‑coding RNAs in glioblastoma
Ji, J., Zhao, L., Zhao, X., Li, Q., An, Y., Li, L., & Li, D. (2020) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2020.4579 · Cited by 15
Grady, C. I., Walsh, L. M., & Heiss, J. D. (2023) · Frontiers in Neurology · doi:10.3389/fneur.2023.1154753 · Cited by 17
Whole-Genome Multi-omic Study of Survival in Patients with Glioblastoma Multiforme
Rubio, Y. L. B., González-Reymúndez, A., Wu, K.-H., Griguer, C. E., Steibel, J. P., Campos, G. D. L., Doseff, A. I., Gallo, K. A., & Vazquez, A. I. (2018) · G3 Genes Genomes Genetics · doi:10.1534/g3.118.200391 · Cited by 15
Kan, S., Chai, S., Chen, W., & Yu, B. (2019) · Oncology Letters · doi:10.3892/ol.2019.10512 · Cited by 12
“The patient details are presented in the original study by Lai et al (17).”
BackgroundMethodInfluentialNamdar, L., Vardi, J., Paz, Y., & Sapir‐Hen, L. (2021) · Archaeological and Anthropological Sciences · doi:10.1007/s12520-021-01446-6 · Cited by 15
Relationship between mast cells and E-cadherin in odontogenic keratocysts and radicular cysts
Pinheiro, J. C., de Carvalho, C. H. P., Galvão, H. C., Pinto, L. P., de Souza, L. B., & Santos, P. P. D. A. (2019) · Clinical Oral Investigations · doi:10.1007/s00784-019-02929-6 · Cited by 11
Pereira, G. C. (2017) · Springer eBooks · doi:10.1007/978-3-319-53880-8_11 · Cited by 10
Kirschner, S. M., & Rodenkirch, R. (2017) · Animal Reproduction Science · doi:10.1016/j.anireprosci.2017.07.016 · Cited by 9
RETRACTED ARTICLE: BET inhibitor I-BET151 sensitizes GBM cells to temozolomide via PUMA induction
Yao, Z., Yang, S., Zhao, H., Yang, H., & Jiang, X. J. (2018) · Cancer Gene Therapy · doi:10.1038/s41417-018-0068-4 · Cited by 9
RetractedDNA Hydroxymethylation in High-Grade Gliomas
Stapińska-Syniec, A., Grabiec, M., Rylski, M., Acewicz, A., & Sobstyl, M. R. (2021) · Journal of Neurological Surgery Part A Central European Neurosurgery · doi:10.1055/a-1713-7699 · Cited by 8
“DNA methylation and hydroxymethylation play an important role in the regulation of gene expression during carcinogenesis of different tumors [10-15].”
BackgroundInfluentialLiang, B., Wang, Y., Huang, J., Lin, S., Mao, G., Zhou, Z., Yan, W., Shan, C., Wu, H., Etcheverry, A., et al. (2023) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14465 · Cited by 8
Kersch, C. N., Claunch, C. J., Ambady, P., Bucher, E., Schwartz, D. L., Barajas, R., Iliff, J. J., Risom, T., Heiser, L. M., Muldoon, L. L., et al. (2020) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdaa093 · Cited by 7
Landscape of the oncogenic role of fatty acid synthase in human tumors
Huo, X., Song, L., Li, D., Wang, K., Wang, Y., Chen, F., Zhang, L., Wang, L., Zhang, J., & Wu, Z. (2021) · Aging · doi:10.18632/aging.203730 · Cited by 6
“We used the GSE50923 dataset [19] to assess the methylation status in 54 GBM tissues and 24 normal brain tissues.”
MethodWang, J., Zhang, M., Liu, Y.-F., Yao, Y., Ji, Y.-S., Etcheverry, A., Chen, K., Song, B., Lin, W. J., Yin, A., et al. (2022) · Epigenomics · doi:10.2217/epi-2022-0344 · Cited by 5
Yin, A., Yao, Y., Liu, Y.-F., Ji, Y., He, Y., Ma, T., Guo, W.-H., Etcheverry, A., Aubry, M., Mosser, J., et al. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06360-2 · Cited by 6
“These datasets were sourced from The Cancer Genome Atlas (TCGA) [15, 16], the Gene Expression Omnibus (GEO) [17–22], and the Chinese Glioma Genome Atlas (CGGA) [23].”
Accuracy of GEBV of sires based on pooled allele frequency of their progeny
Jurado, N. V., Kuehn, L. A., Keele, J. W., & Lewis, R. M. (2021) · G3 Genes Genomes Genetics · doi:10.1093/g3journal/jkab231 · Cited by 4
Kit, O. I., Vodolazhsky, D. I., Rostorguev, E. E., Frantsiyants, E. M., & Panina, S. (2017) · Molecular Genetics Microbiology and Virology · doi:10.3103/s0891416817040036 · Cited by 3
“Among the hypermethylated signaling pathways of genes, the transcriptional regulatory network specific to embryonic stem cells was the most significant [66].”
BackgroundInfluentialMolecular genetic markers of gliomas
Kit, O. I., Vodolazhsky, D. I., Rostorguev, E. E., Frantsiian, E. M., & Panina, S. (2017) · Molecular Genetics Microbiology and Virology (Russian) · doi:10.18821/0208-0613-2017-35-4-132-140 · Cited by 2
Bibliometric and visualization analysis in the field of epigenetics and glioma (2009–2024)
Zeng, Y., Tao, G., Zeng, Y., He, J., Cao, H., & Zhang, L. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1431636 · Cited by 1
Exploring ATM and Methylation in Cancer: Emphasizing on Brain Tumors
Mehdipour, P., & Karami, F. (2015) · Springer eBooks · doi:10.1007/978-94-017-9639-2_6 · Cited by 1
“FLJ36268, ZNF146 and GUP1 (Lai et al. 2014).”
Burns, A. M. (2015) · DigitalCommons@UNMC
Liu, L., Wang, G., Wang, L., Yu, C., Li, M., Song, S., Hao, L., Ma, L., & Zhang, Z. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/798785
“Using the four independent datasets from D5-GSE36278-M (Sturm et al., 2012), V8-GSE50923-M (Lai et al., 2014), V9-GSE61160-M (Mur et al., 2013) and V10-CGGA-M (Zhang et al., 2013), we found that cg26626089 is significantly hyper-methylated in GBM patients compared with normal samples (Figure 3A and 3C; p-value < 0.01,…”
InfluentialDNA methylation as a prognostic marker in clear cell Renal Cell Carcinoma
Andersson-Evelönn, E. (2020) · DiVA at Umeå University (Umeå University)
Li, B., Liu, F., Hu, W., Li, R., Etcheverry, A., Aubry, M., Mosser, J., Zhang, X., Wu, Y., Yin, A., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-823543/v1
Mustafin, R. N. (2026) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2026.1002408
Metadata
- Authors
- Lai, R. K., Chen, Y., Guan, X., Nousome, D., Sharma, C., Canoll, P., Bruce, J., Sloan, A. E., Cortes, E., Vonsattel, J.-P., Su, T., Delgado-Cruzata, L., Gurvich, I., Santella, R. M., Ostrom, Q., Lee, A., Gregersen, P., & Barnholtz-Sloan, J.
- Affiliations
- University of Southern California (US)
- Case Comprehensive Cancer Center (US)
- Columbia University (US)
- University Hospitals Cleveland Medical Center (US)
- Herbert Irving Comprehensive Cancer Center (US)
- North Shore University Hospital (US)
- Corresponding author
- Lai, Rose K.
- ORCID
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2014-02-21
- Volume
- 9
- Issue
- 2
- Pages
- e89376
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3931727
- OpenAlex
- W2036863866
- Cited by
- 54
- References
- 46
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 1 · 2023: 3 · 2022: 1 · 2021: 9 · 2020: 6 · 2019: 5 · 2018: 5 · 2017: 8 · 2016: 4 · 2015: 9
- FWCI
- 2.87
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- CUNY Academic Works (City University of New York) (submittedVersion, cc-by)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Columbia Academic Commons (Columbia University)
- Funders
- National Institutes of Health
- National Cancer Institute (K07CA127468, R01CA139020, R01CA139020-27064, P30CA043703, P30CA014089)
- National Institute of Environmental Health Sciences (P30ES009089)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer-related molecular mechanisms research
- Keywords
- glioblastoma, DNA methylation, differentially methylated genes, promoter hypermethylation, promoter hypomethylation, LINE-1 retrotransposons, 5-methylcytosine, 5-hydroxymethylcytosine, immune pathways, stem cell differentiation, prognostic factors, overall survival, epigenetic therapy targets
- MeSH terms
- Adult, Aged, Aged, 80 and over, Brain, Brain Neoplasms, Female, Glioblastoma, Humans, Male, Middle Aged, Promoter Regions, Genetic, CpG Islands, DNA Methylation, Genome-Wide Association Study
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.